Bacterial infections represent a rapidly growing challenge to human health. Aminoglycosides are widely used broad-spectrum antibiotics, but they inflict permanent hearing loss in up to ~50% of patients by causing selective sensory hair cell loss. Here, we hypothesized that reducing aminoglycoside entry into hair cells via mechanotransducer channels would reduce ototoxicity, and therefore we synthesized 9 aminoglycosides with modifications based on biophysical properties of the hair cell mechanotransducer channel and interactions between aminoglycosides and the bacterial ribosome. Compared with the parent aminoglycoside sisomicin, all 9 derivatives displayed no or reduced ototoxicity, with the lead compound N1MS 17 times less ototoxic and with reduced penetration of hair cell mechanotransducer channels in rat cochlear cultures. Both N1MS and sisomicin suppressed growth of *E. coli* and *K. pneumoniae*, with N1MS exhibiting superior activity against extended spectrum β-lactamase producers, despite diminished activity against *P. aeruginosa* and *S. aureus*. Moreover, systemic sisomicin treatment of mice resulted in 75% to 85% hair cell loss and profound hearing loss, whereas N1MS treatment preserved both hair cells and hearing. Finally, in mice with *E. coli*-infected bladders, systemic N1MS treatment eliminated bacteria from urinary tract tissues and serially collected urine samples, without compromising auditory and kidney functions. Together, our findings establish N1MS as a nonototoxic aminoglycoside and support targeted modification as a promising approach to generating nonototoxic antibiotics.
Designer aminoglycosides prevent cochlear hair cell loss and hearing loss

Markus E. Huth,1 Kyu-Hee Han,1 Kayvon Sotoudeh,1 Yi-Ju Hsieh,2 Thomas Effertz,1 Andrew A. Vu,1 Sarah Verhoeven,1 Michael H. Hsieh,2 Robert Greenhouse,1 Alan G. Cheng,1,3 and Anthony J. Ricci1,4

1Department of Otolaryngology — Head and Neck Surgery, 2Department of Urology, 3Department of Pediatrics, and 4Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California, USA.

Abstract

Bacterial infections represent a rapidly growing challenge to human health. Aminoglycosides are widely used broad-spectrum antibiotics, but they inflict permanent hearing loss in up to ~50% of patients by causing selective sensory hair cell loss. Here, we hypothesized that reducing aminoglycoside entry into hair cells via mechanotransducer channels would reduce ototoxicity, and therefore we synthesized 9 aminoglycosides with modifications based on biophysical properties of the hair cell mechanotransducer channel and interactions between aminoglycosides and the bacterial ribosome. Compared with the parent aminoglycoside sisomicin, all 9 derivatives displayed no or reduced ototoxicity, with the lead compound N1MS 17 times less ototoxic and with reduced penetration of hair cell mechanotransducer channels in rat cochlear cultures. Both N1MS and sisomicin suppressed growth of E. coli and K. pneumoniae, with N1MS exhibiting superior activity against extended spectrum β-lactamase producers, despite diminished activity against P. aeruginosa and S. aureus. Moreover, systemic sisomicin treatment of mice resulted in 75% to 85% hair cell loss and profound hearing loss, whereas N1MS treatment preserved both hair cells and hearing. Finally, in mice with E. coli–infected bladders, systemic N1MS treatment eliminated bacteria from urinary tract tissues and serially collected urine samples, without compromising auditory and kidney functions. Together, our findings establish N1MS as a nonototoxic aminoglycoside and support targeted modification as a promising approach to generating nonototoxic antibiotics.

Introduction

Bacterial infections commonly overwhelm host defenses and require antimicrobial therapy. For over twenty years and despite newer alternative antibiotics, aminoglycosides remain the mainstay treatment worldwide for numerous disease entities, including pneumonia, peritonitis, sepsis, and genitourinary tract infection (1, 2). The salient features of aminoglycosides include potent antimicrobial activities and minimal drug-related allergies. On the other hand, their major limiting side effects are nephrotoxicity, loss of vestibular function, and permanent hearing impairment, which is detected in approximately 20% of treated patients using conventional audiometry (3, 4). When higher frequency hearing is examined, hearing loss is found in almost half of treated patients (47%) (5). This prevalence may be even higher at longer periods after treatment when considering the prolonged half-life of drug in the inner ear cochlea and the irreversible nature of cochlear hair cell loss (6). Despite these side effects, the World Health Organization recommends aminoglycosides as critically important antimicrobials for clinical use (7). At present, aminoglycoside-induced hearing loss represents one of the most common iatrogenic and preventable forms of hearing loss.

In both humans and animals, aminoglycosides cause hearing loss by inducing sensory hair cell degeneration (3, 4). The drug is first transported across the blood-labyrinth barrier to enter the endolymph-filled inner ear compartments (8). It then traverses the mechanotransducer channels or other cation channels to enter hair cells (9–11), resulting in cell demise most likely as a result of the generation of reactive oxygen species (3, 12). Past efforts to neutralize aminoglycoside ototoxicity have emphasized the administration of antioxidants, yet the efficacy of this approach is limited (4, 13–15), in part because of the long half-life of aminoglycosides once they enter hair cells (6).

Alternatively, recent studies suggest that structural differences of the aminoglycoside compounds may contribute to differential ototoxicity (16, 17). In particular, apramycin, an aminoglycoside used in veterinary medicine, is less toxic to hair cells, and its diminished toxicity is correlated with its lower affinity to eukaryotic ribosomes than bacterial ribosomes (16). Although this is a proof of concept that different chemical sites on the aminoglycoside contribute to antimicrobial activity and ototoxicity, several aminoglycoside derivatives exhibit decreased ototoxicity yet lack antibacterial activity (18). Thus, a mechanism to modify aminoglycoside to eliminate its ototoxic effects while preserving its antimicrobial effect remains elusive.

Inner ear hair cells are mechanoreceptors uniquely equipped with mechanotransducer (MET) channels located on their stereociliary bundles (19). Because aminoglycoside transport via the
Results

Novel aminoglycoside derivatives exhibit decreased ototoxicity in vitro. Electrochemical gradients drive cations through the hair cell MET channels (Figure 1A and ref. 24). Although the molecular nature of this channel remains controversial, a significant body of literature exists on the biophysical properties (24, 26–30). Given that aminoglycosides are permeable blockers of the MET channel, we hypothesized that targeted modification to reduce positively charged sites on the aminoglycoside molecule would hinder drug entry into hair cells and thus prevent ototoxicity (9). Using established synthetic methods (31), we first chemically protected 3 of the amine groups on the aminoglycoside sisomicin, a biosynthetic precursor of gentamicin, thus allowing subsequent modification of the N1 and/or N3′′ amine site (Supplemental Figure 1, A and B; supplemental material available online with this article; doi:10.1172/JCI77424DS1). Sisomicin was selected because it is
commercially available at high purity (>98%) as compared with gentamicin. We selected 3 moieties (methylsulfonyl [MS], phenylsulfonfyl [PS], and benzoyl [BZ]) to modify these 2 amine groups (1 and 3′) (Figure 1B and Supplemental Figure 1B), which were predicted by X-ray crystallography as dispensable sites for the bacterial ribosome binding-dependent antimicrobial effects of aminoglycosides (25). These functional groups were conjugated to the 1 amine group (N1MS, N1PS, N1BZ), 3′ amine group (N3′MS, N3′PS, N3′BZ), or both the 1 and 3′ amine groups (N1,3′MS, N1,3′PS, N1,3′BZ) of sisomicin (Figure 1B, Supplemental Figure 1C, and Supplemental Figure 2). The chemical synthetic schemes are detailed in Supplemental Figure 1 and ref. 32.

Like gentamicin, sisomicin (200 μM for 1 hour) caused a basal-apical gradient of hair cell loss in in rat cochlear cultures (Figure 1C–H, and Supplemental Table 1). At the molar equivalent of the parent compound sisomicin (200 μM), all 9 new sisomicin derivatives induced markedly less hair cell loss, with 4 compounds showing almost no hair cell toxicity (Figure 1G and Supplemental Table 1). Conjugation with the MS moiety was more effective than that with either the PS or BZ structures in ameliorating ototoxicity (Supplemental Figure 3, A–C), and all 3 modifications of the sisomicin backbone with the MS moiety eliminated ototoxicity (Supplemental Figure 3, D–F). Dose-response experiments (drug exposure for 1 hour, as above) showed that N1MS (>95% pure, Supplemental Figure 2) is 17 times less toxic than sisomicin (98% pure, K0 = 100 ± 2 μM and 1.7 ± 0.2 mM, respectively; Figure 1H and Supplemental Table 2). These data suggest that specific modification of aminoglycosides effectively reduced toxicity against hair cells in vitro.

Novel aminoglycoside derivatives show antibacterial activities in vitro. Enterobacteriaceae rank among the most frequently isolated organisms from patients (33). Based on this, we next tested the antimicrobial activities of sisomicin and its derivatives against E. coli in vitro. Sisomicin and 2 sisomicin derivatives (N1MS and N1PS) showed comparable minimal inhibitory and bactericidal concentrations (using a concentration of <4 μg/ml to define antimicrobial activity; ref. 34 and Figure 2). All 6 compounds modified at the 3′ amine site showed diminished antimicrobial effects (N3′MS, N3′PS, N3′BZ, N1,3′MS, N1,3′PS, N1,3′BZ; Figure 2).

Because N1MS displayed the most favorable antibacterial activity-ototoxicity profile, it was further tested against clinical isolates of E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus. Similar to sisomicin, gentamicin, and tobramycin, N1MS effectively suppressed growth of most E. coli strains (9 of 10), including all 3 extended spectrum β-lactamase-producing (ESBL-producing) strains (Figure 3A), which are multidrug resistant and known to be associated with high rates of patient mortality (35, 36). N1MS inhibited 8 of 10 K. pneumoniae strains (including 3 of 5 ESBL producers), whereas sisomicin was active against 6 of 10 strains (1 of 5 ESBL producers; Figure 3B). Compared with sisomicin, N1MS showed diminished activities against P. aeruginosa and S. aureus strains (P < 0.05 for both; Figure 3, C and D). While modifying the 3′ amine group abolished antibacterial activities of all 6 sisomicin derivatives (Figure 2), 3 of 6 (N3′PS, N1,3′PS, N1,3′BZ) compounds retained some ototoxic effects (Supplemental Figure 3). Conversely, modifying the 1 amine alone reduced the spectrum of antibacterial effects; enhanced activity against E. coli and K. pneumoniae, consistent with previous results on the aminoglycoside apramycin (16). However, the findings that N1MS showed decreased toxicity against hair cells (17 times less ototoxic), P. aeruginosa species (22 times less ototoxic), and S. aureus species (18 times less ototoxic) suggest that such dissociation may be species specific. Whether loss of antibacterial activity results from decreased entry into bacteria (2) and/or diminished interaction with bacterial ribosomes remains to be determined.

Novel aminoglycoside shows diminished entry via hair cell MET channels. Aminoglycosides are permeant blockers of the hair cell MET channels (10, 24, 27). To assess aminoglycoside trafficking across MET channels, electrophysiological measurements of rat cochlear hair cells were performed in vitro. As expected, sisomicin (100 μM) reduced inward currents elicited by mechanical stimulation (Figure 4A). In comparison, current amplitudes in the presence of an identical concentration of N1MS were larger, indicating that N1MS acted as a lower affinity blocker for the MET channels.

Furthermore, voltage clamping of hair cells showed decreased inward and outward currents in the presence of sisomicin or N1MS across all voltages tested (Figure 4, A and B). The nonlinear voltage-current relationships after drug treatment (sisomicin or N1MS) suggest that both drugs acted as permeant blockers, whose ability to reduce MET channel currents (and thus block the channel) was diminished at the most negative and positive holding potentials. Dose-response experiments at a holding potential of ~80 mV
showed that drug concentrations blocking 50% of MET channel currents were lower for sisomicin than N1MS (KD showed that drug concentrations blocking 50% of MET channel currents were lower for sisomicin than N1MS (KD = 65.0 ± 17.7 and 4.9 ± 17.7 μM, respectively) (Figure 4C). Likewise, at the other negative holding potentials examined, the KD for sisomicin was significantly lower than that for N1MS (KD = 65.0 ± 17.7 and 4.9 ± 17.7 μM, respectively) (Figure 4C). Taken together and considering that N1MS is less likely to traverse the hair cell MET channel and thus enter hair cells than the parent compound sisomicin.

**Novel aminoglycosides prevent hair cell loss and hearing loss in vivo.**

To compare the ototoxicity of sisomicin and N1MS in vivo, we tested them in a deafness paradigm in mice (37). By challenging 30-day-old normal hearing CBA/CaJ mice with a combination of sisomicin and a loop diuretic (single injection of 175 mg/kg sisomicin followed by 300 mg/kg furosemide; Figure 5A), we induced substantially elevated thresholds in auditory brainstem responses (ABRs) and distortion product otoacoustic emissions (DPOAEs) 1 and 5–6 weeks later (Figure 5, C, E, and F). In contrast, we detected no significant threshold shifts in ABR and DPOAE measurements, except a shift from 8 to 17 dB at the 2 highest frequencies, 1 and 5–6 weeks after N1MS treatment (Figure 5, D–F).

Surface preparation of cochleae from sisomicin-treated mice displayed extensive outer hair cell loss in the middle and basal turns (16.9 ± 10.1% and 11.1 ± 10.5% of saline-treated controls, P < 0.001 for both; n = 9 mice; Figure 6, A and B, and Supplemental Table 3), corresponding to loss of auditory function in those animals. Conversely, cochleae from N1MS-treated animals showed substantially more hair cells than sisomicin-treated animals, and thus less toxicity, 1 week and 5–6 weeks after treatment (Supplemental Table 3), consistent with their auditory measurements, which were comparable to those of saline-injected animals (Figure 5, E and F).

To rule out collateral toxicity by sisomicin and N1MS outside the auditory system, 35 different types of organs were examined 3 days after drug administration. Among 5 sisomicin-treated animals, acute renal tubular epithelial degeneration was detected in 2 animals, whereas no tissue toxicity was detected in any of the 10 N1MS-treated animals (Supplemental Table 4). Moreover, we performed dose–response experiments in vivo to determine drug doses that induced animal death and found that sisomicin was lethal at lower doses than N1MS (LD_{50}: 200 ± 2 mg/kg and 544 ± 7 mg/kg, respectively; Supplemental Figure 4). Based on this, we tested the effects of higher sublethal doses of N1MS and combined it with loop diuretic challenge (400 mg/kg N1MS and 300 mg/kg furosemide). While sisomicin caused ~100% animal mortality at this dose, >95% N1MS-treated animals survived for over a month under these conditions. After treatment with N1MS at this higher dose, there were marked ABR and DPOAE threshold shifts with cor-
The Journal of Clinical Investigation

Research Article

25-g animal) effectively suppressed bacteriuria (Figure 7, B–D). Moreover, bladder and kidney homogenates collected on day 6 demonstrated that both sisomicin and N1MS reduced bacterial titers in urinary tract issues (Figure 7, E and F). One week after treatment, N1MS- and sisomicin-treated mice exhibited normal ABR and DPOAE waveforms and thresholds and also normal serum creatinine levels (625 μg for both; Supplemental Figure 5). In summary, these results indicate that N1MS is effective at eliminating E. coli–mediated urinary tract infection, without compromising auditory and kidney functions.

Discussion

Aminoglycosides are potent antibiotics that are actively used worldwide, with ototoxicity being the major dose-limiting side effect. Our study uses a novel chemical synthetic approach for alleviating aminoglycoside ototoxicity while preserving anti-

Figure 4. Hair cell MET responses at different membrane holding potentials after sisomicin and N1MS treatment. (A and B) Mechanical stimulation (a negative step of 650 nm for 0.1 ms, then a positive step of 650 nm for 5 ms) was used to stimulate hair cell hair bundles at different membrane holding potentials (stepped from -180 to +120 in 20-mV increments). Responses to mechanical stimuli were obtained at different holding potentials to generate the current responses shown in the absence and presence of sisomicin (red) or N1MS (blue, both at 100 μM). Sisomicin reduced current amplitudes more effectively than N1MS and thus acts as a higher affinity blocker for the MET channel. Current-voltage plots show that sisomicin reduced both inward (at negative potentials) and outward currents (at positive potentials) and displayed loss of block at both extreme negative and positive steps, indicating that sisomicin acts as a permeant blocker of the MET channel. Measurements under identical conditions found that blockage with N1MS was markedly diminished. (C) Remaining fraction of control current for sisomicin and N1MS at a holding potential of -120 mV at different concentrations (10, 30, 100, 300, and 1,000 μM). (D) K_d derived from remaining control current fraction for sisomicin and N1MS at different holding potentials and concentrations (-180 to +120, 20-mV increments). Data are shown as average ± SD. n = 2–9.

Novel aminoglycosides eradicate urinary tract infection. E. coli is the most common pathogen causing urinary tract infections (38). To test whether N1MS is effective against urinary tract infections, we inoculated mouse urinary tracts with a uropathogenic strain of E. coli (39) followed by treatment with 5 sequential injections of sisomicin or N1MS (Figure 7A). In comparison with saline-injected controls, from which serially collected urine consistently yielded high titers of E. coli, both sisomicin and N1MS effectively eliminated bacteria from urine collected 1, 4, and 6 days after inoculation (Figure 7, B–D). All 3 concentrations of N1MS (25, 125, and 625 μg at 5 doses per 20-
bacterial activity. We modified the aminoglycoside compound based on the notion that hindering aminoglycoside entry via hair cell MET channel prevents ototoxicity (9, 20). The design was based on the biophysical properties of the MET channel (24, 26), whose candidate molecular compositions are still being elucidated (22, 40–42). Nonetheless, electrochemical gradients drive cations through the MET channel; therefore, the conversion of basic amine sites of aminoglycosides into carboxamides or sulfonamides renders them nonbasic (less positively charged) and was predicted to decrease drug entry and subsequent toxicity. Our paradigm produced sisomicin derivatives exhibiting diminished in vitro toxicity relative to the parent compound sisomicin, with the lead compound N1MS less capable of crossing the MET channels than sisomicin. While the electrophysiological measurements were made in vitro to assess drug entry across the MET channel, the electrochemical gradient present in vivo in the intact cochlea is substantially larger. This difference may in part account for the 17-fold decreased ototoxicity in vitro and 2.3-fold decreased ototoxicity in vivo between N1MS and sisomicin. As the MET channel pore size is estimated at 1.25 ± 0.08 nm at its narrowest segment (24), it is possible that the larger sizes of sisomicin derivatives may have also impeded drug entry. However, the effects of compound dimension are likely limited, as the moieties added were relatively small. Thus, future experiments using bulkier moieties may further delineate the relationships among aminoglycoside dimensions and drug entry and ototoxicity.

A rich body of literature supports the hypothesis that oxidative stress mediates aminoglycoside-induced hair cell degeneration (12, 43), yet the initial events that generate reactive oxygen species are poorly understood. Building upon the knowledge that the human mitochondrial mutation A1555G (GenBank accession no. NC 012920) increases the risk of hearing loss after aminoglycoside treatment (44), recent work has revealed the potential roles of mitochondrial stress in aminoglycoside ototoxicity (16, 45). In particular, work on apramycin, a structurally unique aminoglycoside used in veterinary medicine, suggests that its differential antiribosomal activities against eukaryotic cells versus bacteria contribute to its low ototoxic potential. Moreover, recent work suggests that aminoglycosides induce hair cell toxicity by causing ribotoxic stress and in turn inhibit cytoplasmic protein synthesis (46). While our data support the conclusion that decreased drug entry via MET channels underlies diminished aminoglycoside ototoxicity, we did not determine whether sisomicin and sisomicin derivatives differentially bind eukaryotic and bacterial ribosomes, induce ribotoxic stress, or inhibit protein synthesis in hair cells. One or all of these mechanisms may have also contributed to N1MS’s decreased ototoxicity.

Because aminoglycosides can provide broad coverage of gram-negative organisms, they are widely used when the offending organisms are unknown, such as in the setting of neonatal sepsis or peritonitis (47, 48). Additionally, aminoglycosides are clinically indicated for treating pneumonia caused by *P. aeruginosa* and urinary tract infection caused by *E. coli* (2). Differential binding affinities for  

---

**Figure 5. Modified aminoglycoside prevents hearing loss.** (A) Schematic of drug treatment to deafen 30-day-old CBA/CaJ mice. (B) Representative ABR tracings in a saline-treated mice showing a 30 dB SPL threshold at 23 kHz. (C) Sisomicin-treated (175 mg/kg) mice showed no detectable responses. (D) In contrast, mice administered with N1MS (175 mg/kg) exhibited normal auditory responses (thresholds = 0 dB SPL). (E and F) ABRs and DPOAEs of animals administered saline 1 week prior (magenta), 175 mg/kg sisomicin 1 week prior (black), 175 mg/kg N1MS 1 week prior (red), 175 mg/kg sisomicin 5–6 weeks prior (green), 175 mg/kg N1MS 5 to 6 weeks prior (blue), and 400 mg/kg N1MS 1 week prior (cyan). Sisomicin-treated animals had elevated ABR and DPOAE thresholds in comparison to saline-treated animals, whereas N1MS-treated animals had robust ABR and DPOAE signals 1 and 5–6 weeks after treatment. High-dose sisomicin treatment was lethal (Supplemental Figure 5). High-dose N1MS treatment caused elevated ABR and DPOAE thresholds. Data are shown as average ± SEM. For E and F, *n* = 57 for saline control; *n* = 9–14 for other groups.
Aminoglycoside-induced vestibulotoxicity presents both as a dose and duration effect for systemic infection (4) and as an intended therapeutic effect, such as for Meniere’s disease (51). However, the current study did not directly compare whether sisomicin and its derivatives differ in their vestibular hair cell toxicity; such a comparison may help determine the candidacy of aminoglycoside derivatives as clinical therapeutics.

As ototoxicity limits both the dose and duration of aminoglycoside treatment, our study provides proof-of-concept data supporting targeted modification of aminoglycosides as an effective strategy to prevent iatrogenic hearing loss. Future studies modifying other aminoglycoside compounds may help generate a family of aminoglycoside antibiotics with minimized risk of ototoxicity and thus add to the armamentarium of antibiotics.
tamicin by the Clinical and Laboratory Standards Institute (34). An antibiotic concentration of <4 μg/ml as the criteria, as defined for gen-

Inoculated tubes were incubated at 37°C overnight. The lowest antibiotic concentration sufficient to inhibit bacterial growth (an absence of bacterial growth) was defined as the minimum inhibitory concentration (MIC). To determine antibiotic efficacy, we used a bacterial pellet at the bottom of the tube) was defined as the minimum biotic concentration sufficient to inhibit bacterial growth (an absence of bacterial growth). Whereas tissues feature high bacterial titers in the absence of antibiotic treatment, both sisomicin and N1MS reduced colony formation, especially at the higher doses. **n = 10** for B-F.

**Mouse model of urinary tract infection.** Procedures were performed as previously described (39). Briefly, type I pili expression was induced in the uropathogenic *E. coli* strain UTI89 by inoculating bacteria into the bladders of female 7- to 8-week-old CBA/CaJ mice by transurethral catheterization. For drug treatment, infected mice were injected subcutaneously with sisomicin or N1MS (25–625 μg) dissolved in 100 μl PBS every 2 hours for a total of 5 injections after UTI89 infection.

Aseptically excised bladders and kidneys were minced and homoge-

To determine the minimum bactericidal concentration (MBC) of the aminoglycoside compounds, we streaked out 50 μl from aminoglycoside-containing, bacteria-inoculated tubes that exhibited no bacterial growth. Whereas tissues feature high bacterial titers in the absence of antibiotic treatment, both sisomicin and N1MS reduced colony formation, especially at the higher doses. **n = 10** for B-F.

**Bacterial culture.** Antimicrobial activity was measured by incubating serial dilutions of sisomicin or derivatives with a constant bacterial inoculum. *E. coli* XL blue (Agilent Technologies) was incubated in 3 ml Müller-Hinton broth (Becton Dickenson) at 37°C overnight to generate static phase cultures. The following day, incubation tubes were inoculated with 10⁶ CFU bacteria. Serial 2-fold dilutions of the aminoglycoside compounds (0.03–64 μg/ml) were added to 2 ml Müller-Hinton broth (54). The inoculated tubes were incubated at 37°C overnight. The lowest antibiotic concentration sufficient to inhibit bacterial growth (an absence of bacterial growth) was defined as the minimum inhibitory concentration (MIC). To determine antibiotic efficacy, we used an antibiotic concentration of <4 μg/ml as the criteria, as defined for gentamicin by the Clinical and Laboratory Standards Institute (34).

Microscopic imaging and quantification. Tissues were imaged using a confocal laser scanning microscope (Zeiss LSM 5 Pascal AxioVert 200M, Carl Zeiss AG). The cochlea was divided into 3 regions (base, middle, and apex), and 1 or 2 areas per region were imaged. In every area, outer hair cells were counted.

**Bacterial culture.** Antimicrobial activity was measured by incubating serial dilutions of sisomicin or derivatives with a constant bacterial inoculum. *E. coli* XL blue (Agilent Technologies) was incubated in 3 ml Müller-Hinton broth (Becton Dickenson) at 37°C overnight to generate static phase cultures. The following day, incubation tubes were inoculated with 10⁶ CFU bacteria. Serial 2-fold dilutions of the aminoglycoside compounds (0.03–64 μg/ml) were added to 2 ml Müller-Hinton broth (54). The inoculated tubes were incubated at 37°C overnight. The lowest antibiotic concentration sufficient to inhibit bacterial growth (an absence of bacterial growth) was defined as the minimum inhibitory concentration (MIC). To determine antibiotic efficacy, we used an antibiotic concentration of <4 μg/ml as the criteria, as defined for gentamicin by the Clinical and Laboratory Standards Institute (34).
overnight incubation at 37°C. The limits of detection were 4,000 CFU/ml for urine and 160 CFU per bladder. To determine creatinine levels, 25 μl of serum was collected from each mouse and sent to the Diagnostic Laboratory of Veterinary Service Center at Stanford University.

**Auditory measurements.** ABRs and DPOAEs were measured as previously described with custom hardware based around a data acquisition board (PCOe-6251, National Instruments) driven by software written in MATLAB (Mathworks) (55, 56). Briefly, mice were sedated with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). ABR signals were measured from a needle electrode positioned inferior to the tympanic bulla, referenced to an electrode placed at the vertex of the head, and a ground electrode was placed at the hind leg. Tone burst stimuli were delivered with frequencies ranging from 4 to 64 kHz (4, 8, 16, 32, 64 kHz) and sound intensities raised from 10 to 80 dB sound pressure level (SPL) in 10-dB steps. At each frequency and sound level, 260 trials were sampled and averaged.

DPOAEs were measured by a probe tip microphone in the external auditory canal. The sound stimuli were two 1-second sine wave tones of differing frequencies (F2 = 1.22 × F1). F2 was varied from 4 to 46 kHz, and the intensities of 2 tones were from 20 to 80 dB SPL with 10-dB steps. The amplitude of the cubic distortion product was measured at 2 × F1–F2. The threshold at each frequency was calculated to be when the DPOAE was >5 dB SPL and 2 SDs above the noise level. For statistical analyses of both ABR and DPOAE responses, a lack of response is designated 80 dB SPL.

**Histology of organs (necropsy).** All procedures were performed by a board-certified veterinary pathologist at the Diagnostic Laboratory of Veterinary Service Center at Stanford University. First, a complete gross examination of organs and tissues was performed. A comprehensive list of organs and tissues was sampled (Supplemental Table 4), and gross examination of organs and tissues was performed. A comprehensive list of organs and tissues was sampled (Supplemental Table 4), and specimens of organs (necropsy) were fixed in 10% neutral buffered formalin. Histology of inner ear tissues and fluids with other organs was carried out in accordance with institutional guidelines at Stanford University.

**Acknowledgments**

The authors thank Y. Shi and S. Billings for critical reading; M. Traczewski, S. Brown, L. Alexandrova, S. Lynch, R. Luong, and K. Comstock for excellent technical assistance; and D. Moehly-Rosen, K. Grimes, and other Stanford SPARK members for fruitful discussion. We are grateful for support from NIH/NIDCD (P30DC010363), Swiss National Science Foundation (PBSP3 130635/1 to M.E. Huth), NIH/NIDDK (K08DK087895 to M.H. Hsieh), NIH/NIDCD (K08DC011043 and RO1DC019190), Akiko Yamazaki and Jerry Yang Faculty Scholar Fund (to A.G. Cheng), NIH/NIDCD (R21DC012183 and RO1DC003896), Stanford SPARK program, and Child Health Research Institute funding (to A.J. Ricci).

**Address correspondence to:** Alan G. Cheng or Anthony J. Ricci, 801 Welch Road, Department of Otolaryngology-HNS, Stanford, California 94305, USA. Phone: 650.725.6500; E-mail: agcheng@stanford.edu (A.G. Cheng), aricci@ohns.stanford.edu (A.J. Ricci).

Markus E. Huth’s present address is: Department of Otolar- yngology, Head and Neck Surgery, University Hospital Bern, Frei- burgstrasse, Bern, Switzerland.

Yi-Ju Hsieh and Michael H. Hsieh’s present address is: Biomedical Research Institute, Rockville, Maryland, USA.

**Statistics.** Data were analyzed using Microsoft Excel (Microsoft), GraphPad Prism, and Origin softwares (OriginLab). Two-tailed Student’s t tests and analysis of covariance were performed. When multiple t tests were performed, Bonferroni correction was included. P < 0.05 was considered statistically significant.

**Study approval.** Sprague Dawley rats (Charles River Laboratories) and CBA/CaJ mice (The Jackson Laboratory) were used. Animal care and all experimental procedures were carried out in accordance with institutional guidelines at Stanford University.


19. Beug M, Fettiplace R, Nam JH, Ricci AJ. Local-


